Tamoxifen

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Cytostatic, antiestrogen.

See also under "Targeted tumour therapeutics"(aromatase inhibitors).

Half-lifeThis section has been translated automatically.

168–240 h

IndicationThis section has been translated automatically.

Breast cancer in the postmenopause. Metastatic malignant melanoma ( off-label use).

Dosage and method of useThis section has been translated automatically.

20-40 mg/day p.o.

Undesirable effectsThis section has been translated automatically.

Edema, vaginal bleeding, thrombo- and leucopenia, depression, allergic skin reactions, headaches, hot flashes, hyperhidrosis. Rarely blood count, liver or kidney disorders. The risk of endometrial carcinoma is 5 times higher.

So-called radiation recall dermatitis has been described, initiated by previous exposure to radiation or UV light.

ContraindicationThis section has been translated automatically.

Women of childbearing age.

PreparationsThis section has been translated automatically.

Nolvadex®, Tamoxifen-ratiopharm®

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer